Application of mRNA Immunotherapy Technology in Epstein-Barr Virus-related Refractory Malignant Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

February 8, 2023

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions
Malignant Tumors
Interventions
BIOLOGICAL

EBV mRNA vaccine

With 25ug as the starting point, the dose was increased using a dose escalation scheme. Each subject only received one corresponding dose, and intramuscular injection was administered again every 7 days, and after 4 doses, the 5th dose was given after 1 month interval

Trial Locations (1)

610041

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors
lead

West China Hospital

OTHER